₨60.00
No
Lincomycin
Bacterial Infection
Lincomycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the bacterial ribosome. Lincomycin is predominantly bacteriostatic in vitro.
Adults : 600 mg by IM inj 12-24 hrly or IV infusion 8-12 hrly. Children : Under 1 mnth , not recommended ; others , 10 mg/kg by IM inj 12-24 hrly ; alternatively 10-20 mg/kg daily by IV infusion in 2 or 3 divided doses at 8-12 hr intervals. OR As directed by your physician.
Skin and subcutaneous tissue disorders : Toxic epidermal necrolysis, Stevens-Johnson syndrome, acute generalized exanthematous pustulosis, dermatitis bullous, dermatitis exfoliative, erythema multiforme, rash, urticaria, pruritusInfections and infestations : Vaginal infection, pseudomembranous colitis, Clostridium difficile colitis .Blood and lymphatic system disorders : Pancytopenia, agranulocytosis, aplastic anemia, leukopenia, neutropenia, thrombocytopenic purpuraImmune system disorders : Anaphylactic reaction , angioedema, serum sicknessHepatobiliary disorders : Jaundice, liver function test abnormal, transaminases increasedRenal and urinary disorders : Renal impairment, oliguria, proteinuria, azotemiaCardiac disorders : Cardio-respiratory arrest Vascular disorders : Hypotension , thrombophlebitisEar and labyrinth disorders : Vertigo, tinnitusNeurologic disorders : Headache, dizziness, somnolence
Kanamycin, novobiocin and phenytoin , neuromuscular blocking medicines (muscle-relaxing medicines) .
The specific infections for which lincomycin is used include: ear, throat and lung infections; skin infections; bone and joint infections; and infections of the blood.
Do not take Lincomycin if you have an allergy to: • Clindamycin or lincomycin • Any of the other ingredients listed.
The use of Lincomycin may result in overgrowth of nonsusceptible organisms— particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation. When patients with pre-existing monilial infections require therapy with Lincomycin, concomitant antimonilial treatment should be given.
Severe hypersensitivity reactions, including anaphylactic reactions and severe cutaneous adverse reactions (SCAR) such as Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute generalized exanthematous pustulosis (AGEP), and erythema multiforme (EM) have been reported in patients receiving LINCOCIN therapy. If an anaphylactic reaction or severe skin reaction occurs, Lincomycin should be discontinued and appropriate therapy should be initiated.
It should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.
Do not use this drug in patients with nonbacterial infections
Always consult your physician before using any medicine.
Store this medicine at room temperature, away from direct light and heat.